Merck Reports P-III Trial (LITESPARK-005) Results of Welireg (belzutifan) for Patients with Advanced Renal Cell Carcinoma
Shots:
- The P-III trial evaluating Welireg vs everolimus in 736 patients with advanced RCC that have progressed after prior treatment with PD-1/L1 and VEGF-TKI therapies
- The trial met 1EPs i.e., clinical improvement in PFS based on a pre-specified interim analysis conducted by IDMC, improvement in 2EPs of ORR was also observed. Additionally, trends toward improvement in OS did not reach statistical significance
- The safety profile was consistent with prior reported studies & the results will be presented at an upcoming medical meeting and shared with regulatory authorities. Welireg was approved in the US, Great Britain, Canada & multiple other countries for adult patients with von Hippel-Lindau (VHL) disease
Ref: Businesswire | Image: Merck
Related News:- Merck's Welireg (belzutifan) Receives the US FDA's Approval for the Treatment of Von Hippel-Lindau Disease Associated Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
